Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
Launched by UNIVERSITY OF PITTSBURGH · Nov 28, 2005
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the outcomes of two different types of surgery for esophageal cancer: minimally invasive esophagectomy (MIE) and open esophagectomy. The researchers want to see how these surgeries affect patients in both the short term and long term, focusing especially on the quality of life after the surgery. Quality of life means how well patients feel and function in their daily lives after the procedure. The study is currently recruiting participants aged 65 to 74 who are scheduled for either type of surgery and can provide informed consent.
Participants in this trial can expect to be part of a study that compares their recovery and overall well-being after surgery. They will fill out surveys about their quality of life to help researchers understand how each surgical method affects them. It's important to note that those who cannot understand or complete these surveys or are under 18 years old will not be eligible for the study. This trial aims to provide valuable insights into the best surgical options for patients with esophageal cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients scheduled for MIE (Minimally Invasive Esophagectomy)
- • Patients scheduled for open esophagectomy
- • Signed informed consent
- Exclusion Criteria:
- • Patients who are unable to comprehend or complete the QOL instruments.
- • Patients less than 18 years of age.
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
James D Luketich, MD
Principal Investigator
UPMC - Department of Cardiothoracic Surgery
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials